APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

CD20 Monoclonal Antibodies

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global CD20 Monoclonal Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025190 pages

Choose your research edition.

Industry ResearchCD20 Monoclonal Antibodies Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal CD20 Monoclonal Antibodies Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal CD20 Monoclonal Antibodies Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CD20 Monoclonal Antibodies Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal CD20 Monoclonal Antibodies Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global CD20 Monoclonal Antibodies market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for CD20 Monoclonal Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for CD20 Monoclonal Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CD20 Monoclonal Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for CD20 Monoclonal Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of CD20 Monoclonal Antibodies include Chia Tai-Tianqing Pharmaceutical, Innovent Biologics, Shanghai Institute of Biological Products, Shanghai Henlius Biotec, TG Therapeutics, Teva, Roche, Pfizer and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global CD20 Monoclonal Antibodies market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of CD20 Monoclonal Antibodies and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents CD20 Monoclonal Antibodies sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the CD20 Monoclonal Antibodies market size, projected growth trends, production technologies, key applications, and end-use industries.

CD20 Monoclonal Antibodies Segment by Company

Chia Tai-Tianqing Pharmaceutical

Innovent Biologics

Shanghai Institute of Biological Products

Shanghai Henlius Biotec

TG Therapeutics

Teva

Roche

Pfizer

Novartis

Celltrion

Biogen

Amgen

CD20 Monoclonal Antibodies Segment by Type

Chimeric Antibodies

Humanized Antibodies

Fully Human Antibodies

CD20 Monoclonal Antibodies Segment by Application

Relapsing Multiple Sclerosis

Non-Hodgkin's lymphoma

Leukemia

Other

CD20 Monoclonal Antibodies Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CD20 Monoclonal Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CD20 Monoclonal Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CD20 Monoclonal Antibodies.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the CD20 Monoclonal Antibodies market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of CD20 Monoclonal Antibodies manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of CD20 Monoclonal Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of CD20 Monoclonal Antibodies in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. CD20 Monoclonal Antibodies Industry Trends Table 2. CD20 Monoclonal Antibodies Industry Drivers Table 3. CD20 Monoclonal Antibodies Industry Opportunities and Challenges Table 4. CD20 Monoclonal Antibodies Industry Restraints Table 5. Global CD20 Monoclonal Antibodies Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global CD20 Monoclonal Antibodies Revenue Market Share by Manufacturers (2021-2026) Table 7. Global CD20 Monoclonal Antibodies Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global CD20 Monoclonal Antibodies Sales Market Share by Manufacturers Table 9. Global CD20 Monoclonal Antibodies Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global CD20 Monoclonal Antibodies Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global CD20 Monoclonal Antibodies Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global CD20 Monoclonal Antibodies Manufacturers, Product Type & Application Table 13. Global CD20 Monoclonal Antibodies Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global CD20 Monoclonal Antibodies by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Chimeric Antibodies Table 17. Major Manufacturers of Humanized Antibodies Table 18. Major Manufacturers of Fully Human Antibodies Table 19. Global CD20 Monoclonal Antibodies Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global CD20 Monoclonal Antibodies Sales by Type (2021-2026) & (K Units) Table 21. Global CD20 Monoclonal Antibodies Sales by Type (2027-2032) & (K Units) Table 22. Global CD20 Monoclonal Antibodies Sales Market Share by Type (2021-2026) Table 23. Global CD20 Monoclonal Antibodies Sales Market Share by Type (2027-2032) Table 24. Global CD20 Monoclonal Antibodies Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global CD20 Monoclonal Antibodies Revenue by Type (2021-2026) & (K Units) Table 26. Global CD20 Monoclonal Antibodies Revenue by Type (2027-2032) & (K Units) Table 27. Global CD20 Monoclonal Antibodies Revenue Market Share by Type (2021-2026) Table 28. Global CD20 Monoclonal Antibodies Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Relapsing Multiple Sclerosis Table 30. Major Manufacturers of Non-Hodgkin's lymphoma Table 31. Major Manufacturers of Leukemia Table 32. Major Manufacturers of Other Table 33. Global CD20 Monoclonal Antibodies Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global CD20 Monoclonal Antibodies Sales by Application (2021-2026) & (K Units) Table 35. Global CD20 Monoclonal Antibodies Sales by Application (2027-2032) & (K Units) Table 36. Global CD20 Monoclonal Antibodies Sales Market Share by Application (2021-2026) Table 37. Global CD20 Monoclonal Antibodies Sales Market Share by Application (2027-2032) Table 38. Global CD20 Monoclonal Antibodies Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global CD20 Monoclonal Antibodies Revenue by Application (2021-2026) & (K Units) Table 40. Global CD20 Monoclonal Antibodies Revenue by Application (2027-2032) & (K Units) Table 41. Global CD20 Monoclonal Antibodies Revenue Market Share by Application (2021-2026) Table 42. Global CD20 Monoclonal Antibodies Revenue Market Share by Application (2027-2032) Table 43. Global CD20 Monoclonal Antibodies Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global CD20 Monoclonal Antibodies Sales by Region (2021-2026) & (K Units) Table 45. Global CD20 Monoclonal Antibodies Sales Market Share by Region (2021-2026) Table 46. Global CD20 Monoclonal Antibodies Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global CD20 Monoclonal Antibodies Sales Forecasted Market Share by Region (2027-2032) Table 48. North America CD20 Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America CD20 Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 50. North America CD20 Monoclonal Antibodies Sales by Country (2027-2032) & (K Units) Table 51. Europe CD20 Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe CD20 Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 53. Europe CD20 Monoclonal Antibodies Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific CD20 Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific CD20 Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific CD20 Monoclonal Antibodies Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa CD20 Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa CD20 Monoclonal Antibodies Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa CD20 Monoclonal Antibodies Sales by Country (2027-2032) & (K Units) Table 60. Global CD20 Monoclonal Antibodies Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global CD20 Monoclonal Antibodies Revenue by Region (2021-2026) & (US$ Million) Table 62. Global CD20 Monoclonal Antibodies Revenue by Region (2027-2032) & (US$ Million) Table 63. Global CD20 Monoclonal Antibodies Revenue Market Share by Region (2021-2026) Table 64. Global CD20 Monoclonal Antibodies Revenue Market Share by Region (2027-2032) Table 65. Chia Tai-Tianqing Pharmaceutical Company Information Table 66. Chia Tai-Tianqing Pharmaceutical Business Overview Table 67. Chia Tai-Tianqing Pharmaceutical CD20 Monoclonal Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Chia Tai-Tianqing Pharmaceutical CD20 Monoclonal Antibodies Product Portfolio Table 69. Chia Tai-Tianqing Pharmaceutical Recent Development Table 70. Innovent Biologics Company Information Table 71. Innovent Biologics Business Overview Table 72. Innovent Biologics CD20 Monoclonal Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Innovent Biologics CD20 Monoclonal Antibodies Product Portfolio Table 74. Innovent Biologics Recent Development Table 75. Shanghai Institute of Biological Products Company Information Table 76. Shanghai Institute of Biological Products Business Overview Table 77. Shanghai Institute of Biological Products CD20 Monoclonal Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Shanghai Institute of Biological Products CD20 Monoclonal Antibodies Product Portfolio Table 79. Shanghai Institute of Biological Products Recent Development Table 80. Shanghai Henlius Biotec Company Information Table 81. Shanghai Henlius Biotec Business Overview Table 82. Shanghai Henlius Biotec CD20 Monoclonal Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Shanghai Henlius Biotec CD20 Monoclonal Antibodies Product Portfolio Table 84. Shanghai Henlius Biotec Recent Development Table 85. TG Therapeutics Company Information Table 86. TG Therapeutics Business Overview Table 87. TG Therapeutics CD20 Monoclonal Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. TG Therapeutics CD20 Monoclonal Antibodies Product Portfolio Table 89. TG Therapeutics Recent Development Table 90. Teva Company Information Table 91. Teva Business Overview Table 92. Teva CD20 Monoclonal Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Teva CD20 Monoclonal Antibodies Product Portfolio Table 94. Teva Recent Development Table 95. Roche Company Information Table 96. Roche Business Overview Table 97. Roche CD20 Monoclonal Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Roche CD20 Monoclonal Antibodies Product Portfolio Table 99. Roche Recent Development Table 100. Pfizer Company Information Table 101. Pfizer Business Overview Table 102. Pfizer CD20 Monoclonal Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Pfizer CD20 Monoclonal Antibodies Product Portfolio Table 104. Pfizer Recent Development Table 105. Novartis Company Information Table 106. Novartis Business Overview Table 107. Novartis CD20 Monoclonal Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Novartis CD20 Monoclonal Antibodies Product Portfolio Table 109. Novartis Recent Development Table 110. Celltrion Company Information Table 111. Celltrion Business Overview Table 112. Celltrion CD20 Monoclonal Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Celltrion CD20 Monoclonal Antibodies Product Portfolio Table 114. Celltrion Recent Development Table 115. Biogen Company Information Table 116. Biogen Business Overview Table 117. Biogen CD20 Monoclonal Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Biogen CD20 Monoclonal Antibodies Product Portfolio Table 119. Biogen Recent Development Table 120. Amgen Company Information Table 121. Amgen Business Overview Table 122. Amgen CD20 Monoclonal Antibodies Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Amgen CD20 Monoclonal Antibodies Product Portfolio Table 124. Amgen Recent Development Table 125. Key Raw Materials Table 126. Raw Materials Key Suppliers Table 127. CD20 Monoclonal Antibodies Distributors List Table 128. CD20 Monoclonal Antibodies Customers List Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. CD20 Monoclonal Antibodies Product Image Figure 2. Global CD20 Monoclonal Antibodies Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CD20 Monoclonal Antibodies Market Size (2021-2032) & (US$ Million) Figure 4. Global CD20 Monoclonal Antibodies Sales (2021-2032) & (K Units) Figure 5. Global CD20 Monoclonal Antibodies Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 CD20 Monoclonal Antibodies Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Chimeric Antibodies Image Figure 9. Humanized Antibodies Image Figure 10. Fully Human Antibodies Image Figure 11. Global CD20 Monoclonal Antibodies Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global CD20 Monoclonal Antibodies Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global CD20 Monoclonal Antibodies Sales Market Share by Type (2021-2032) Figure 14. Global CD20 Monoclonal Antibodies Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global CD20 Monoclonal Antibodies Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global CD20 Monoclonal Antibodies Revenue Market Share by Type (2021-2032) Figure 17. Relapsing Multiple Sclerosis Image Figure 18. Non-Hodgkin's lymphoma Image Figure 19. Leukemia Image Figure 20. Other Image Figure 21. Global CD20 Monoclonal Antibodies Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global CD20 Monoclonal Antibodies Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global CD20 Monoclonal Antibodies Sales Market Share by Application (2021-2032) Figure 24. Global CD20 Monoclonal Antibodies Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global CD20 Monoclonal Antibodies Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global CD20 Monoclonal Antibodies Revenue Market Share by Application (2021-2032) Figure 27. North America CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America CD20 Monoclonal Antibodies Sales Market Share by Country (2021-2032) Figure 29. U.S. CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe CD20 Monoclonal Antibodies Sales Market Share by Country (2021-2032) Figure 34. Germany CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific CD20 Monoclonal Antibodies Sales Market Share by Country (2021-2032) Figure 41. China CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa CD20 Monoclonal Antibodies Sales Market Share by Country (2021-2032) Figure 49. Brazil CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile CD20 Monoclonal Antibodies Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global CD20 Monoclonal Antibodies Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global CD20 Monoclonal Antibodies Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America CD20 Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Figure 60. North America CD20 Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe CD20 Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Figure 62. Europe CD20 Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific CD20 Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific CD20 Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa CD20 Monoclonal Antibodies Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa CD20 Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. CD20 Monoclonal Antibodies Value Chain Figure 68. Manufacturing Cost Structure Figure 69. CD20 Monoclonal Antibodies Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Chimeric Antibodies
  • Humanized Antibodies
  • Fully Human Antibodies
Applications
  • Relapsing Multiple Sclerosis
  • Non-Hodgkin's lymphoma
  • Leukemia
  • Other
Companies covered
  • Chia Tai-Tianqing Pharmaceutical
  • Innovent Biologics
  • Shanghai Institute of Biological Products
  • Shanghai Henlius Biotec
  • TG Therapeutics
  • Teva
  • Roche
  • Pfizer
  • Novartis
  • Celltrion
  • Biogen
  • Amgen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global CD20 Monoclonal Antibodies Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global CD20 Monoclonal Antibodies Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global CD20 Monoclonal Antibodies Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global CD20 Monoclonal Antibodies Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global CD20 Monoclonal Antibodies Market Dynamics
  1. 2.1 CD20 Monoclonal Antibodies Industry Trends
  2. 2.2 CD20 Monoclonal Antibodies Industry Drivers
  3. 2.3 CD20 Monoclonal Antibodies Industry Opportunities and Challenges
  4. 2.4 CD20 Monoclonal Antibodies Industry Restraints
3 CD20 Monoclonal Antibodies Market by Manufacturers
  1. 3.1 Global CD20 Monoclonal Antibodies Revenue by Manufacturers (2021-2026)
  2. 3.2 Global CD20 Monoclonal Antibodies Sales by Manufacturers (2021-2026)
  3. 3.3 Global CD20 Monoclonal Antibodies Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global CD20 Monoclonal Antibodies Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global CD20 Monoclonal Antibodies Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global CD20 Monoclonal Antibodies Manufacturers, Product Type & Application
  7. 3.7 Global CD20 Monoclonal Antibodies Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global CD20 Monoclonal Antibodies Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 CD20 Monoclonal Antibodies Players Market Share by Revenue in 2025
  11. 3.8.3 2025 CD20 Monoclonal Antibodies Tier 1, Tier 2, and Tier 3
4 CD20 Monoclonal Antibodies Market by Type
  1. 4.1 CD20 Monoclonal Antibodies Type Introduction
  2. 4.1.1 Chimeric Antibodies
  3. 4.1.2 Humanized Antibodies
  4. 4.1.3 Fully Human Antibodies
  5. 4.2 Global CD20 Monoclonal Antibodies Sales by Type
  6. 4.2.1 Global CD20 Monoclonal Antibodies Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global CD20 Monoclonal Antibodies Sales by Type (2021-2032)
  8. 4.2.3 Global CD20 Monoclonal Antibodies Sales Market Share by Type (2021-2032)
  9. 4.3 Global CD20 Monoclonal Antibodies Revenue by Type
  10. 4.3.1 Global CD20 Monoclonal Antibodies Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global CD20 Monoclonal Antibodies Revenue by Type (2021-2032)
  12. 4.3.3 Global CD20 Monoclonal Antibodies Revenue Market Share by Type (2021-2032)
5 CD20 Monoclonal Antibodies Market by Application
  1. 5.1 CD20 Monoclonal Antibodies Application Introduction
  2. 5.1.1 Relapsing Multiple Sclerosis
  3. 5.1.2 Non-Hodgkin's lymphoma
  4. 5.1.3 Leukemia
  5. 5.1.4 Other
  6. 5.2 Global CD20 Monoclonal Antibodies Sales by Application
  7. 5.2.1 Global CD20 Monoclonal Antibodies Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global CD20 Monoclonal Antibodies Sales by Application (2021-2032)
  9. 5.2.3 Global CD20 Monoclonal Antibodies Sales Market Share by Application (2021-2032)
  10. 5.3 Global CD20 Monoclonal Antibodies Revenue by Application
  11. 5.3.1 Global CD20 Monoclonal Antibodies Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global CD20 Monoclonal Antibodies Revenue by Application (2021-2032)
  13. 5.3.3 Global CD20 Monoclonal Antibodies Revenue Market Share by Application (2021-2032)
6 Global CD20 Monoclonal Antibodies Sales by Region
  1. 6.1 Global CD20 Monoclonal Antibodies Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global CD20 Monoclonal Antibodies Sales by Region (2021-2032)
  3. 6.2.1 Global CD20 Monoclonal Antibodies Sales by Region (2021-2026)
  4. 6.2.2 Global CD20 Monoclonal Antibodies Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America CD20 Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America CD20 Monoclonal Antibodies Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe CD20 Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe CD20 Monoclonal Antibodies Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific CD20 Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific CD20 Monoclonal Antibodies Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa CD20 Monoclonal Antibodies Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa CD20 Monoclonal Antibodies Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global CD20 Monoclonal Antibodies Revenue by Region
  1. 7.1 Global CD20 Monoclonal Antibodies Revenue by Region
  2. 7.1.1 Global CD20 Monoclonal Antibodies Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global CD20 Monoclonal Antibodies Revenue by Region (2021-2026)
  4. 7.1.3 Global CD20 Monoclonal Antibodies Revenue by Region (2027-2032)
  5. 7.1.4 Global CD20 Monoclonal Antibodies Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America CD20 Monoclonal Antibodies Revenue (2021-2032)
  8. 7.2.2 North America CD20 Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe CD20 Monoclonal Antibodies Revenue (2021-2032)
  11. 7.3.2 Europe CD20 Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific CD20 Monoclonal Antibodies Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific CD20 Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa CD20 Monoclonal Antibodies Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa CD20 Monoclonal Antibodies Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Chia Tai-Tianqing Pharmaceutical
  2. 8.1.1 Chia Tai-Tianqing Pharmaceutical Company Information
  3. 8.1.2 Chia Tai-Tianqing Pharmaceutical Business Overview
  4. 8.1.3 Chia Tai-Tianqing Pharmaceutical CD20 Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Chia Tai-Tianqing Pharmaceutical CD20 Monoclonal Antibodies Product Portfolio
  6. 8.1.5 Chia Tai-Tianqing Pharmaceutical Recent Developments
  7. 8.2 Innovent Biologics
  8. 8.2.1 Innovent Biologics Company Information
  9. 8.2.2 Innovent Biologics Business Overview
  10. 8.2.3 Innovent Biologics CD20 Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Innovent Biologics CD20 Monoclonal Antibodies Product Portfolio
  12. 8.2.5 Innovent Biologics Recent Developments
  13. 8.3 Shanghai Institute of Biological Products
  14. 8.3.1 Shanghai Institute of Biological Products Company Information
  15. 8.3.2 Shanghai Institute of Biological Products Business Overview
  16. 8.3.3 Shanghai Institute of Biological Products CD20 Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Shanghai Institute of Biological Products CD20 Monoclonal Antibodies Product Portfolio
  18. 8.3.5 Shanghai Institute of Biological Products Recent Developments
  19. 8.4 Shanghai Henlius Biotec
  20. 8.4.1 Shanghai Henlius Biotec Company Information
  21. 8.4.2 Shanghai Henlius Biotec Business Overview
  22. 8.4.3 Shanghai Henlius Biotec CD20 Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Shanghai Henlius Biotec CD20 Monoclonal Antibodies Product Portfolio
  24. 8.4.5 Shanghai Henlius Biotec Recent Developments
  25. 8.5 TG Therapeutics
  26. 8.5.1 TG Therapeutics Company Information
  27. 8.5.2 TG Therapeutics Business Overview
  28. 8.5.3 TG Therapeutics CD20 Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 TG Therapeutics CD20 Monoclonal Antibodies Product Portfolio
  30. 8.5.5 TG Therapeutics Recent Developments
  31. 8.6 Teva
  32. 8.6.1 Teva Company Information
  33. 8.6.2 Teva Business Overview
  34. 8.6.3 Teva CD20 Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Teva CD20 Monoclonal Antibodies Product Portfolio
  36. 8.6.5 Teva Recent Developments
  37. 8.7 Roche
  38. 8.7.1 Roche Company Information
  39. 8.7.2 Roche Business Overview
  40. 8.7.3 Roche CD20 Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Roche CD20 Monoclonal Antibodies Product Portfolio
  42. 8.7.5 Roche Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer CD20 Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer CD20 Monoclonal Antibodies Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Novartis
  50. 8.9.1 Novartis Company Information
  51. 8.9.2 Novartis Business Overview
  52. 8.9.3 Novartis CD20 Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Novartis CD20 Monoclonal Antibodies Product Portfolio
  54. 8.9.5 Novartis Recent Developments
  55. 8.10 Celltrion
  56. 8.10.1 Celltrion Company Information
  57. 8.10.2 Celltrion Business Overview
  58. 8.10.3 Celltrion CD20 Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Celltrion CD20 Monoclonal Antibodies Product Portfolio
  60. 8.10.5 Celltrion Recent Developments
  61. 8.11 Biogen
  62. 8.11.1 Biogen Company Information
  63. 8.11.2 Biogen Business Overview
  64. 8.11.3 Biogen CD20 Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Biogen CD20 Monoclonal Antibodies Product Portfolio
  66. 8.11.5 Biogen Recent Developments
  67. 8.12 Amgen
  68. 8.12.1 Amgen Company Information
  69. 8.12.2 Amgen Business Overview
  70. 8.12.3 Amgen CD20 Monoclonal Antibodies Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Amgen CD20 Monoclonal Antibodies Product Portfolio
  72. 8.12.5 Amgen Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 CD20 Monoclonal Antibodies Value Chain Analysis
  2. 9.1.1 CD20 Monoclonal Antibodies Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 CD20 Monoclonal Antibodies Production Mode & Process
  6. 9.2 CD20 Monoclonal Antibodies Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 CD20 Monoclonal Antibodies Distributors
  9. 9.2.3 CD20 Monoclonal Antibodies Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst